$259.61 5.7 2.2%
Last Trade - 01/02/17
| Market Cap | £25.71bn |
| Enterprise Value | £29.20bn |
| Revenue | £8.12bn |
| Position in Universe | th / 7386 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 10,764 | 11,449 | 12,274 | 13,453 | 14,378 | 13,445 | 10,873 | 10,390 | +4.5% | ||
| +27.0 | +19.1 | -3.4 | +31.4 | +38.0 | -20.8 | -26.0 | -1.99 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2022
|
31st Dec 2023
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.
| Last Annual | December 31st, 2020 |
| Last Interim | September 30th, 2021 |
| Incorporated | April 1, 1997 |
| Public Since | September 17, 1991 |
| No. of Shareholders: | 505 |
| No. of Employees: | 9,100 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | NASDAQ Global Select Market (Dual Listing) |
| Shares in Issue | 146,892,712 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 225 Binney St, CAMBRIDGE, 02142-1031, United States |
| Web | https://www.biogen.com/ |
| Phone | +1 781 4642000 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 01/02/17, shares in Biogen Inc are trading at $259.61, giving the company a market capitalisation of £25.71bn. This share price information is delayed by 15 minutes.
Shares in Biogen Inc are currently trading at $259.61 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biogen Inc price has moved by % over the past year.
There are no analysts currently covering Biogen Inc.
Biogen Inc is scheduled to issue upcoming financial results on the following dates:
Biogen Inc does not currently pay a dividend.
Biogen Inc does not currently pay a dividend.
Biogen Inc does not currently pay a dividend.
To buy shares in Biogen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biogen Inc are currently trading at $259.61, giving the company a market capitalisation of £25.71bn.
Here are the trading details for Biogen Inc:
We were not able to load our ranking data for Biogen Inc
We were not able to load any forecast data for Biogen Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biogen Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $259.61, shares in Biogen Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biogen Inc.
Biogen Inc's management team is headed by:
Here are the top five shareholders of Biogen Inc based on the size of their shareholding:
